RemeGen Co (HKSE:09995) Scaled Net Operating Assets : N/A (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

RemeGen Co's operating assets for the quarter that ended in Dec. 2023 was HK$5,271.1 Mil. RemeGen Co's operating liabilities for the quarter that ended in Dec. 2023 was HK$908.9 Mil. RemeGen Co's Total Assets for the quarter that ended in Sep. 2023 was HK$0.0 Mil. Therefore, RemeGen Co's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was N/A.

RemeGen Co Scaled Net Operating Assets Historical Data

The historical data trend for RemeGen Co's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Scaled Net Operating Assets Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

Get a 7-Day Free Trial

-0.37

1.58

0.45

0.68

0.65

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial									-	0.59	-	-	-

Competitive Comparison of RemeGen Co's Scaled Net Operating Assets

For the Biotechnology subindustry, RemeGen Co's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Scaled Net Operating Assets falls into.

RemeGen Co Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

RemeGen Co's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(5271.106	-	908.921)	/	6723.953
=	0.65

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	6046.675	-	775.569
=	5271.106

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2287.063	-	1001.095	-	377.047
=	908.921

RemeGen Co's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Sep. 2023 )
=	(5271.106	-	908.921)	/	0
=	N/A

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	6046.675	-	775.569
=	5271.106

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2287.063	-	1001.095	-	377.047
=	908.921

RemeGen Co Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines